**Supplementary File 2**

**Calculation of Short-Term Survival, Lifetime Survival, and Incremental Cost-Effectiveness Ratio**

The following algorithms are used in estimating the economic benefit of using angiotensin II on distributive shock patients:

Incremental live saved = [28-day survival rate of angiotensin II arm] – [28-day survival rate of the placebo arm]

Incremental life years gained = [survivor’s discounted life expectancy in angiotensin II arm] – [survivor’s discounted life expectancy in the placebo arm]

Incremental quality-adjusted life years (QALY) gained = [survivor’s QALY in angiotensin II arm] – [survivor’s QALY in the placebo arm]

Incremental cost (short-term) = [total 28-day cost of angiotensin II arm] – [total 28-day cost of the placebo arm]

Incremental cost (long-term) = [total 28-day cost of angiotensin II arm] – [total 28-day cost of the placebo arm]

Incremental cost per life saved = incremental cost/incremental life saved

Incremental cost-effectiveness ratio (ICER) ($/life years gained) = incremental cost/incremental life years gained

ICER ($/QALY) = incremental cost/incremental QALY gained